FDA Approves CAR-T Therapy Tisagenlecleucel for B-Cell Acute Lymphoblastic Leukemia

Share this content:
The FDA approved tisagenlecleucel for the treatment of pediatric and young adult patients up to 25 years of age with acute lymphoblastic leukemia.
The FDA approved tisagenlecleucel for the treatment of pediatric and young adult patients up to 25 years of age with acute lymphoblastic leukemia.

The US Food and Drug Administration (FDA) approved tisagenlecleucel for the treatment of pediatric and young adult patients up to 25 years of age with refractory or in second or later relapse B-cell precursor acute lymphoblastic leukemia (ALL).1

This approval marks the first chimeric antigen receptor T cell (CAR-T) therapy, which utilizes the patients' own genetically-modified T-cells to target the CD19 antigen on the surface of leukemia cells. Once modified, the cells are injected back into the patient.

The FDA based its approval on data collected from the phase 2 ELIANA (ClinicalTrials.gov Identifier: NCT02435849) trial that assessed the outcomes of 63 evaluable pediatric and young adult patients with relapsed or refractory B-cell precursor ALL.

Results showed that 83% of patients (95% CI, 71%-91%) achieved complete response (CR) or CR with incomplete blood count recovery (CRi) within 3 months of treatment. There was also no evidence of minimal residual disease (MRD) ― a marker prognostic for potential relapse ― in patients. A median duration of remission was not reached (95% CI, 7.5 months-not evaluable).

RELATED: Besponsa Approved for B-cell Acute Lymphoblastic Leukemia

The most frequently reported grade 3 or 4 adverse events (AE) cytokine release syndrome and neurologic events. Other commonly occurring AEs include serious infections, hypotension, fever, hypoxia, and acute kidney injury.

Reference

  1. FDA approval brings first gene therapy to the United States [news release]. Silver Spring, MD: US Food and Drug Administration. Updated August 30, 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm. Accessed August 30, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters